26th Steering Committee Meeting
Data Jamboree

The purpose of this meeting is to select up to 15 best of the best research projects being supported by EDRN. This will allow members to be informed of progress that EDRN is making in various tumor types. The Jamboree is divided in five major categories (excluding administrative supplement projects). Each session will start with brief presentations by EDRN investigators who were selected by their collaborative groups. After the presentations, the speakers, a writing team and NCI staff will convene and discuss the data in light of completeness, transformative potential, potential clinical use, potential to change practice, and team science approach. The discussions will also include why the type of work could not have been done without EDRN support.

NCI will also collect updated information on numbers of patents generated by investigators, how EDRN has been leveraged to see support from other funding mechanisms and leveraging resources provided by other sources, etc.

NCI Staff will give a special presentation on the plan to provide information on EDRN progress to the Network Consulting Team in November, 2013 and NCI Board of Scientific Advisors in March or June 2014.
26th EDRN Steering Committee Meeting  
September 10-12, 2013  
Renaissance Seattle Hotel  
Seattle, Washington  

Draft Agenda  

**Tuesday September 10, 2013**  

7:00 – 7:30 a.m.  
Sign-In  

7:30 – 8:30 a.m.  
Opening Session  

7:30 – 7:35 a.m.  
Opening of Steering Committee Meeting  
Ian Thompson, M.D., University of Texas Health Sciences Center at San Antonio  

7:35 – 7:40 a.m.  
Welcome  
Ziding Feng, Ph.D., or Mark Thornquist, Ph.D., Fred Hutchinson Cancer Research Center  

7:40 – 8:00 a.m.  
State of the EDRN  
Sudhir Srivastava, Ph.D., M.P.H., National Cancer Institute  

8:00 – 8:10 a.m.  
Q&A  

8:10 – 8:30 a.m.  
Expectations and Outcomes from Steering Committee Meeting with Q&A  
Joshua LaBaer, M.D., Ph.D., Arizona State University  

8:30 – 9:00 a.m.  
Break  

9:00 a.m. – 12:15 p.m.  
CONCURRENT SESSIONS  
- Session 1: Novel Concepts, Technologies and Study Design  
- Session 2: Targeted Sequencing for the Discovery and/or Validation of Cancer-Specific Biomarkers  

**Session 1: Novel Concepts, Technology and Study Design**  
Moderator: Karin Rodland, Ph.D., Pacific Northwest National Laboratory  

9:00 – 9:15 a.m.  
Title TBD  
Joshua LaBaer, M.D., Ph.D., Arizona State University  

9:15 – 9:25 a.m.  
Q&A
Tuesday September 10, 2013 Continued

Session 1: Novel Concepts, Technology and Study Design Continued

9:25 – 9:40 a.m.  Title TBD
Vadim Backman, Ph.D., Northwestern University

9:40 – 9:50 a.m.  Q&A

9:50 – 10:05 a.m.  SRM-based Targeted Quantification for Candidate Biomarker Verification without Affinity Reagents
David Camp, Ph.D., Pacific Northwest National Laboratory

10:05 – 10:15 a.m.  Q&A

10:15 – 10:30 a.m.  Title TBD
Michael Birrer, M.D., Ph.D., Massachusetts General Hospital

10:30 – 10:40 a.m.  Q&A

10:40 – 11:00 a.m.  Break

11:00 a.m. – 12:15 p.m.  Session 1 Data Jamboree: Analysis and Writing
Analysis Leaders:
o Mark Rubin, M.D., Weill Cornell Medical College
o Karin Rodland, Ph.D., Pacific Northwest National Laboratory

DMCC: TBA
NCI Program Staff: TBA

Format for Data Jamboree: Session speakers and the analysis team assemble and begin data analysis for the purpose of prioritizing and highlighting EDRN accomplishments in light of:
- Completeness of data
- Quality of the studies performed to date (e.g., quality of specimens/data, match between study populations and intended clinical context, blinding, appropriateness of statistical analysis)?
- Transformative potential
- Use in clinical setting
- Practice changer
- Team science approach
### Tuesday September 10, 2013 Continued

#### Session 2: Targeted Sequencing for the Discovery and/or Validation of Cancer-Specific Biomarkers

Moderator: Leslie Ford, M.D., National Cancer Institute

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
</tr>
</thead>
</table>
| 9:00 – 9:15 a.m. | **Title TBD**  
Steven Dubinett, M.D., University of California, Los Angeles |
| 9:15 – 9:25 a.m. | Q&A |
| 9:25 – 9:40 a.m. | **Title TBD**  
Ann Killary, Ph.D., The University of Texas M D Anderson Cancer Center |
| 9:40 – 9:50 a.m. | Q&A |
| 9:50 – 10:05 a.m. | **Title TBD**  
Sanford Markowitz, M.D., Case Western Reserve University |
| 10:05 – 10:15 a.m. | Q&A |
| 10:15 – 10:30 a.m. | **Title TBD**  
David Sidransky, M.D., Johns Hopkins School of Medicine |
| 10:30 – 10:40 a.m. | Q&A |
| **10:30 – 10:40 a.m.** | **Break** |
| **11:00 – 12:15 p.m.** | **Session 2: Review & Recommendations**  
**Reviewers:**  
- Brian Reid, M.D., Ph.D., Fred Hutchinson Cancer Research Center  
- Leslie Ford, M.D., National Cancer Institute  
**DMCC:** TBA  
**NCI Staff:** TBA  
**Format:** Reviewers along with NCI staff will review progress and make recommendations to NCI for on the continuation of the projects. |
| **12:15 – 1:30 p.m.** | **Lunch** |
26th EDRN Steering Committee Meeting  
September 10-12, 2013  
Renaissance Seattle Hotel  
Seattle, Washington  

Tuesday September 10, 2013 Continued

1:30 – 5:45 p.m.  CONCURRENT SESSIONS  
• Session 3: Biomarker Discovery  
• Session 4: Biomarkers to Distinguish Aggressive vs. Non-aggressive Cancers

Session 3: Biomarker Discovery  
Moderator: Harvey Pass, M.D., New York University School of Medicine

1:30 – 1:45 p.m.  Title TBD  
Arul Chinnaiyan, M.D., Ph.D., University of Michigan

1:45 – 1:55 p.m.  Q&A

1:55 – 2:10 p.m.  Title TBD  
David Sidransky, M.D., Johns Hopkins University School of Medicine

2:10 – 2:20 p.m.  Q&A

2:20 – 2:35 p.m.  Title TBD  
Surinder Batra, Ph.D., University of Nebraska Medical Center

2:35 – 2:45 p.m.  Q&A

2:45– 3:05 p.m.  Break

3:05 – 3:20 p.m.  Title TBD  
Sanford Markowitz, M.D., Ph.D., Case Western Reserve University

3:20 – 3:30 p.m.  Q&A

3:30 – 3:45 p.m.  Title TBD  
Ken Kinzler, Ph.D., Johns Hopkins University School of Medicine

3:45 – 3:55 p.m.  Q&A
Tuesday September 10, 2013 Continued

Session 3: Biomarker Discovery Continued

3:55 – 5:45 p.m.  Session 3: Data Jamboree: Analysis and Writing

Analysis Leaders:
  o Ann Killary, Ph.D., The University of Texas M D Anderson Cancer Center
  o Harvey Pass, M.D., New York University

DMCC Staff: TBA
NCI Program Staff: TBA

Format for Data Jamboree: Session speakers and the analysis team assemble and begin data analysis for the purpose of prioritizing and highlighting EDRN accomplishments in light of:
- Completeness of data
- Quality of the studies performed to date (e.g., quality of specimens/data, match between study populations and intended clinical context, blinding, appropriateness of statistical analysis)?
- Transformative potential
- Use in clinical setting
- Practice changer
- Team Science Approach

Session 4:  Biomarkers to Distinguish Aggressive vs. Non-aggressive Cancers

Moderator: Brian Reid, M.D., Ph.D., Fred Hutchinson Cancer Research Center

1:30 – 1:45 p.m.  Title TBD
          William Grady, M.D., Fred Hutchinson Cancer Research Center

1:45 – 1:55 p.m.  Q&A

1:55 – 2:10 p.m.  Title TBD
          Michael (Tony) Hollingsworth, Ph.D., University of Nebraska

2:10 – 2:20 p.m.  Q&A

2:20 –2:35 p.m.  Title TBD
          Christopher Li, M.D., Ph.D., Fred Hutchinson Cancer Research Center

2:35 – 2:45 p.m.  Q&A
Tuesday September 10, 2013 Continued

Session 4: Biomarkers to Distinguish Aggressive vs. Non-aggressive Cancers Continued

2:45 – 3:05 p.m. Break

3:05 – 3:20 p.m. Title TBD
Dan Mercola, M.D., Ph.D., University of California, Irvine

3:20 – 3:30 p.m. Q&A

3:30 – 3:45 p.m. Title TBD
William Rom, M.D., M.P.H., New York University School of Medicine

3:45 – 3:55 p.m. Q&A

3:55 – 4:10 p.m. Title TBD
Ian Thompson, M.D., The University of Texas Health Science Center at San Antonio

4:10 – 4:20 p.m. Q&A

4:20 – 4:35 p.m. Title TBD
Hui Zhang, Ph.D., Johns Hopkins School of Medicine

4:35 – 4:45 p.m. Q&A

4:45 – 5:45 p.m. Session 4: Review & Recommendations

Reviewers:
- Brian Reid, M.D., Ph.D., Fred Hutchinson Cancer Research Center
- Leslie Ford, M.D., National Cancer Institute

DMCC: TBA
NCI Program Staff: TBA

Format: Reviewers along with NCI staff will review progress and make recommendations to NCI on the continuation of the projects.
Wednesday September 11, 2013

7:00 – 8:00 a.m.  Sign-In

8:00 – 11:20 a.m.  CONCURRENT SESSIONS
  •  Session 5: Biomarker Prevalidation
  •  Session 6: Team Science (Part 1)

Session 5: Biomarker Prevalidation
Moderator: Daniel Chan, Ph.D., Johns Hopkins Medical Institutions

8:00 – 8:15 a.m.  Title TBD
  Avi Spira, M.D., Boston University

8:15 – 8:25 a.m.  Q&A

8:25 – 8:40 a.m.  Title TBD
  Jeffrey Marks, Ph.D., Duke University

8:40 – 8:50 a.m.  Q&A

8:50 – 9:05 a.m.  Title TBD
  Harvey Pass, M.D., New York University School of Medicine

9:05 – 9:15 a.m.  Q&A

9:15 – 9:30 a.m.  Title TBD
  Mark Rubin, M.D., Weill Cornell Medical College

9:30 – 9:40 a.m.  Q&A

9:40 –10:00 a.m.  Break

10:00 – 11:20 a.m.  Session 5: Data Jamboree Analysis and Writing

Analysis Leaders:
  o  Dan Chan, Ph.D., Johns Hopkins Medical Institutions
  o  Sanford Stass, M.D., University of Maryland School of Medicine

DMCC Staff: TBA
NCI Program Staff: TBA
Wednesday September 11, 2013 Continued

Session 5: Data Jamboree Analysis and Writing Continued

Format for Data Jamboree: Session speakers and the analysis team assemble and begin data analysis for the purpose of prioritizing and highlighting EDRN accomplishments in light of:

- Completeness of data
- Quality of the studies performed to date (e.g., quality of specimens/data, match between study populations and intended clinical context, blinding, appropriateness of statistical analysis)?
- Transformative
- Use in clinical setting
- Practice changer
- Team Science Approach

Session 6: Team Science (Part 1)
Moderator: William Rom, M.D., New York University School of Medicine

8:00 – 8:15 a.m. Colony Team Project
Robert Schoen, M.D., M.P.H., University of Pittsburgh Cancer Institute

8:15 – 8:25 a.m. Q&A

8:25 – 8:40 a.m. Lung Team Project
Pierre Massion, M.D., Vanderbilt-Ingram Cancer Center

8:40 – 8:50 a.m. Q&A

8:50 – 9:05 a.m. Prostate Team Project 1
Alvin Liu, Ph.D., University of Washington

9:05 – 9:15 a.m. Q&A

9:15 – 9:30 a.m. Prostate Team Project 2
Martin Sanda, M.D., Emory University

9:30 – 9:40 a.m. Q&A

9:40 – 10:00 a.m. Break
Wednesday September 11, 2013 Continued

Session 6: Team Science (Part 1) Continued

10:00 – 11:20 p.m.  
**Session 6: Data Jamboree Analysis and Writing**

Analysis Leaders:
- William Rom, M.D., New York University School of Medicine
- Hemant Roy, M.D., Boston University

DMCC Staff: TBA
NCI Program Staff: TBA

**Format for Data Jamboree:** Session speakers and the analysis team assemble and begin data analysis for the purpose of prioritizing and highlighting EDRN accomplishments in light of:

- Completeness of data
- Quality of the studies performed to date (e.g., quality of specimens/data, match between study populations and intended clinical context, blinding, appropriateness of statistical analysis)?
- Transformative potential
- Use in clinical setting
- Practice changer
- Team Science Approach

11:20 a.m. – 12:00 p.m.  
**Progress toward EDRN Renewal: A Dialogue with EDRN PIs**

- Sudhir Srivastava, Ph.D., M.P.H., National Cancer Institute
- Ian Thompson, M.D., The University of Texas Health Science Center at San Antonio
- Joshua LaBaer, M.D., Ph.D., Arizona State University

12:00 – 1:30 p.m.  
**Lunch (On Your Own)**

12:00 – 1:30 p.m.  
**EDRN Executive Committee Meeting (Closed Session)**

1:30 – 5:30 p.m.  
**CONCURRENT SESSIONS**

- Session 7: Biomarker Validation
- Session 8: Team Science (Part 2)
Wednesday September 11, 2013 Continued

Session 7: Biomarker Validation
Moderator: Arul Chinnaian, M.D., Ph.D. University of Michigan

1:30 – 1:45 p.m. Title TBD
Dean Brenner, M.D., University of Michigan

1:45 – 1:55 p.m. Q&A

1:55 – 2:10 p.m. PCA3
John Wei, M.D., University of Michigan

2:10 – 2:20 p.m. Q&A

2:20 – 2:35 p.m. Canary Active Surveillance Project
James Brooks, M.D., Stanford University Medical Center

2:35 – 2:45 p.m. Q&A

2:45 – 3:00 p.m. Title TBD
Nicole Urban, Sc.D., Fred Hutchinson Cancer Research Center

3:00 – 3:10 p.m. Q&A

3:10 – 3:30 p.m. Break

3:30 – 5:30 p.m. Data Jamboree Session 7: Analysis and Writing

Analysis Leaders:
  o Arul Chinnaian, M.D., Ph.D., University of Michigan
  o Carlo Croce, M.D., The Ohio State University Medical Center

DMCC Staff: TBA
NCI Program Staff: TBA
**Wednesday September 11, 2013 Continued**

**Data Jamboree Session 7: Analysis and Writing Continued**

**Format for Data Jamboree:** Speakers of this session assemble and begin data analysis for the purpose of prioritizing and highlighting EDRN accomplishments in light of:

- Completeness of data
- Quality of the studies performed to date (e.g., quality of specimens/data, match between study populations and intended clinical context, blinding, appropriateness of statistical analysis)?
- Transformative potential
- Use in clinical setting
- Practice changer
- Team Science Approach

**Session 8: Team Science (Part 2)**

Moderator: Subrata Sen, Ph.D., The University of Texas M D Anderson Cancer Center

- **1:30 – 1:45 p.m.**
  - **Breast/Ovarian Team Project 1**
  - Andrew Godwin, Ph.D., Kansas University Medical Center

- **1:45 – 1:55 p.m.**
  - Q&A

- **1:55 – 2:10 p.m.**
  - **Breast/Ovarian Team Project 2**
  - Karen Anderson, M.D., Ph.D., Arizona State University

- **2:10 – 2:20 p.m.**
  - Q&A

- **2:20 – 2:35 p.m.**
  - **Breast/Ovarian Team Project 3**
  - Steve Skates, Ph.D., Massachusetts General Hospital

- **2:35 – 2:45 p.m.**
  - Q&A

- **2:45 – 3:00 p.m.**
  - **miRNA Cross Laboratory Comparison**
  - Marc Salit, Ph.D., National Institute of Standard and Technology

- **3:00 – 3:10 p.m.**
  - Q&A

- **3:10 – 3:25 p.m.**
  - **Pancreatic Cancer Team Project**
  - Brian Haab, Ph.D., Van Andel Research
  - Ann Killary, Ph.D., The University of Texas M D Anderson Cancer Center

- **3:25 – 3:35 p.m.**
  - Q&A
26th EDRN Steering Committee Meeting
September 10-12, 2013
Renaissance Seattle Hotel
Seattle, Washington

Wednesday September 11, 2013 Continued

3:35 – 3:55 p.m. Break

3:55 – 5:30 p.m. Data Jamboree Session 8: Analysis and Writing

Analysis Leaders:
- Subrata Sen, Ph.D., The University of Texas M D Anderson Cancer Center
- Alvin Liu, Ph.D., University of Washington

DMCC Staff: TBA
NCI Staff: TBA

Format for Data Jamboree: Speakers of this session assemble and begin data analysis for the purpose of prioritizing and highlighting EDRN accomplishments in light of:
- Completeness of data
- Quality of the studies performed to date (e.g., quality of specimens/data, match between study populations and intended clinical context, blinding, appropriateness of statistical analysis)?
- Transformative potential
- Use in clinical setting
- Practice changer
- Team Science Approach

Thursday September 12, 2013

7:00 – 7:30 a.m. Sign-In

7:30 – 9:00 a.m. Meeting of Session Analysis Teams
Co-Chairs:
- Ian Thompson, M.D., The University of Texas Health Science Center at San Antonio
- Joshua LaBaer, M.D., Ph.D., Arizona State University

9:00 – 11:00 a.m. Presentations from Analysis Teams (up to 15 projects to highlight EDRN to Network Consulting Team and NCI’s Board of Scientific Advisors)

9:00 – 9:20 a.m. Leader of Analysis Team for Session 1: Novel Concepts, Technologies and Study Design
26th EDRN Steering Committee Meeting  
September 10-12, 2013  
Renaissance Seattle Hotel  
Seattle, Washington  

**Thursday September 12, 2013 Continued**

Presentations from Analysis Teams Continued

9:20 – 9:40 a.m.  Leader of Analysis Team for Session 3: Biomarker Discovery

9:40 – 10:00 a.m.  Leader of Analysis Team for Session 5: Biomarker Prevalidation

10:00 – 10:20 a.m.  Leader of Analysis Team for Session 7: Biomarker Validation

10:20 – 10:40 a.m.  Leader of Analysis Team for Session 6: Team Science 1

10:40 – 11:00 a.m.  Leader of Analysis Team for Session 8: Team Science 2

**11:00 – 11:15 a.m.  Final Remarks**

- Ian Thompson, M.D., The University of Texas Health Science Center at San Antonio
- Sudhir Srivastava, Ph.D., M.P.H., National Cancer Institute

11:15 a.m.  Adjourn